¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå ±Ô¸ð´Â 2025-2030³â CAGR 7.4%·Î È®´ëµÉ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 1¾ï 3,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.
õ½Ä°ú COPDÀÇ ¾ÇÈ È¯ÀÚ¿¡¼ È£Èí¼º Áõ»ó°ú È£Èí ºÎÀüÀÇ ¾Çȸ¦ ÇÇÇϰí ħ½ÀÀûÀÎ ±â°èÀû Àΰø È£Èí ±â°£À» ´ÜÃàÇϰųª ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â´Â °ícapnia È£ÈíºÎÀüÀ» ¾Î°í Àִ ȯÀÚ¿¡ ´ëÇÑ È¿À²ÀûÀÎ Ä¡·á¹ýÀ¸·Î ¿©°ÜÁö°í ÀÖÀ¸¸ç, ÀÓ»óÀǻӸ¸ ¾Æ´Ï¶ó ÇコÄɾî Àü¹®°¡µµ Æóº¸È£ ȯ±â¸¦ °³¼±ÇÒ ¼ö ÀÖÀ» °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ü¿Ü½Ä CO2 Á¦°Å ±â±â´Â ÆóÆ÷ÀÇ ºÐȯ±â·®À» 50% °¨¼Ò½ÃŰ±â¿¡ ÃæºÐÇÑ CO2¸¦ Á¦°ÅÇÒ ¼ö ÀÖÀ¸¸ç, ±× °á°ú PaCO2¸¦ ´ëÆø °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ü¿Ü½Ä CO2 Á¦°Å ±â±â¿Í °ü·ÃµÈ ´Ù¾çÇÑ ÀÌÁ¡Àº ½ÃÀå ÀüüÀÇ ¼ºÀåÀ» Áõ´ë½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â´Â È¿°úÀûÀÌ°í ¾ÈÀüÇÏ¸ç ½ÇÇà °¡´ÉÇÕ´Ï´Ù. ¸¸¼º Æó»ö¼º ÆóÁúȯÀÇ ¾Çȳª ±Þ¼º È£Èí °ï¶õ ÁõÈıº µî ü¿Ü½Ä CO2 Á¦°Å ±â±â°¡ À¯¿ëÇÏ´Ù°í »ý°¢µÇ´Â ÀÓ»ó »óȲ¿¡¼´Â ȯ±â Áö¿ø¿¡¼ÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±âÀÇ »ç¿ëÀÌ ½Ã»çµÇ°í ÀÖ½À´Ï´Ù. ¼¼°è¿¡¼ COPDÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ¾î ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼Ó½Ãų °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¿µ±¹ÆóÇùȸ¿¡ µû¸£¸é ¿µ±¹¿¡¼´Â ¾à 120¸¸ ¸íÀÌ COPD Áø´ÜÀ» ¹Þ°í »ýȰÇϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀÇ ÀϺΠÁ¦Á¶¾÷üµéÀº ±â¼úÀûÀ¸·Î ÷´ÜÀûÀ̰í Çõ½ÅÀûÀΠü¿Ü½Ä CO2 Á¦°Å ±â±âÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ½ÃÀå¿¡¼ÀÇ ÁöÀ§¸¦ °ÈÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2015³â 11¿ù Alung Technologies´Â Hemolung Respiratory Assist System¿¡ ´ëÇØ FDA·ÎºÎÅÍ Expedited Access pathway(EAP)¸¦ ÃëµæÇß½À´Ï´Ù. °Ô´Ù°¡ 2016³â 2¿ù, ¾Ë·î Å×Å©³î·ÎÁö½º´Â ±âÁ¸°ú ½Å±Ô ÅõÀÚÀڷκÎÅÍ 1,200¸¸ ´Þ·¯ÀÇ À¶ÀÚ¸¦ ¹Þ¾Ò½À´Ï´Ù. ÀÌ ÀÚ±Ý Á¶´ÞÀº Hemolung È£Èí º¸Á¶ ½Ã½ºÅÛ(RAS)ÀÇ »ó¾÷È¿¡ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ºÎ¹®Àº 2024³â ½ÃÀå Á¡À¯À²ÀÇ 52.4%¸¦ Â÷ÁöÇÏ°í ½ÃÀåÀ» µ¶Á¡ÇßÀ¸¸ç, ƯÈ÷ Ä¡¸íÀûÀÎ Äɾî ȯ°æ¿¡¼ ȯÀÚÀÇ Ç÷·ù¿¡¼ °úÀ× ÀÌ»êÈź¼Ò¸¦ È¿À²ÀûÀ¸·Î Á¦°ÅÇÏ´Â ¼±ÁøÀû ´É·Â¿¡ ÀÇÇØ ±Þ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
- COPD ºÎ¹®Àº ECCO2R ÀåÄ¡°¡ È£Èí ¼ö¿Í È£Èí·®À» ÁÙÀÏ ¼ö ÀÖ¾î È£Èí±â ½Ã½ºÅÛÀÇ ³ôÀº È£±â ½Ã°£ »ó¼ö¿¡ ÀûÀÀÇÑ ±ä È£±â ½Ã°£À» ÃÊ·¡ÇÒ ¼ö Àֱ⠶§¹®¿¡ 2024³â »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÑ °ÍÀ¸·Î Æò°¡µÇ¾ú½À´Ï´Ù.
- Á¤¸Æ ºÎ¹®Àº µ¿¸Æ Ä«´º·¹À̼ÇÀ» ȸÇÇÇÒ ¼ö Àֱ⠶§¹®¿¡ ħ½À¼ºÀÌ ³·°í, ȯÀÚÀÇ Á¶±â µ¿¿øÀÌ ±â´ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ Áß¿¡ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
- º´¿ø ºÎ¹®Àº ÀÌ·¯ÇÑ Ã·´Ü È£Èí Áö¿øÀ» ÇÊ¿ä·Î ÇÏ´Â º¹ÀâÇÑ ÁßÁõ »ç·Ê¸¦ °ü¸®ÇÏ´Â ´É·ÂÀ¸·Î 2024³â 46.7%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- ºÏ¹ÌÀÇ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀåÀº Àü¹®ÀûÀÎ Äɾî ȯ°æ¿¡¼ÀÇ ÀÓ»ó ä¿ë Áõ°¡¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù.
- À̰ÍÀº COPD, ARDSÀÇ À¯º´·ü Áõ°¡, ¼±ÁøÀû ü¿Ü½Ä CO2 Á¦°Å ±â±âÀÇ Ã¤¿ë Áõ°¡¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅëÀÇ Àü¸Á
- ¸ð ½ÃÀå Àü¸Á
- °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå ºÐ¼® Åø
- »ê¾÷ ºÐ¼®-Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Á¦Ç°º° º¯µ¿ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Á¦Ç°º° Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- ü¿Ü½Ä CO2 ±â±â
- ÀÏȸ¿ë
- ±âŸ
Á¦5Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¿ëµµº° º¯µ¿ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¿ëµµº° Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- ±Þ¼º È£Èí °ï¶õ ÁõÈıº(ARDS)
- ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)
- Æó À̽Ŀ¡ ´ëÇÑ °¡±³
- ±âŸ
Á¦6Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¾×¼¼½ºº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¾×¼¼½ºº° º¯µ¿ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ¾×¼¼½ºº° Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- Á¤¸Æ·ù
- µ¿¸Æ·ù
Á¦7Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- Ŭ¸®´Ð
- ±âŸ
Á¦8Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ªº° ´ë½Ãº¸µå
- Áö¿ªº° ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå º¯µ¿ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Á¦Ç°, ¿ëµµ, Á¢±Ù, ÃÖÁ¾ ¿ëµµ¿¡ ÀÇÇÑ Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ºÐ·ù
- ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Medtronic
- Getinge AB
- Xenios AG
- Medica SPA
- Aferetica srl
- ALung Technologies, Inc.
- ESTOR SPA
- Baxter
- X-COR Therapeutics
AJY 25.05.29
Extracorporeal CO2 Removal Devices Market Growth & Trends:
The global extracorporeal CO2 removal devices market size is estimated to reach USD 137.2 million by 2030, expanding at a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological improvements changed extracorporeal techniques for CO2 removal in promising manner to avoid worsening respiratory acidosis and respiratory failure and to possibly shorten or prevent the duration of invasive mechanical ventilation in patients with exacerbation of asthma and COPD.
Extracorporeal CO2 removal devices is considered to be an efficient therapy for patients suffering from hypercapnia respiratory failure and may allow clinicians as well as healthcare professionals to improve lung protective ventilation. Extracorporeal CO2 removal devices can remove adequate CO2 to allow 50% reduction in alveolar minute ventilation resulting into substantial reduction in PaCO2. Hence, various advantages associated with extracorporeal CO2 removal devices is expected to augment the overall market progression.
Extracorporeal CO2 removal devices are effective, safe and feasible. The usage of extracorporeal CO2 removal devices in ventilation support has been suggested in clinical situations where they may be useful, including exacerbation of chronic obstructive pulmonary disease and acute respiratory distress syndrome. Increasing prevalence of COPD across the globe is predicted to accelerate the market growth. According to the British Lung Association, around 1.2 million people are living with diagnosed COPD in the U.K.
Several manufacturers in the market are focusing on developing technological advanced and innovative extracorporeal CO2 removal devices and strengthen its position in the market. For instance, In November 2015, Alung Technologies received Expedited Access pathway (EAP) from the FDA for its Hemolung Respiratory Assist System. In addition, in February 2016, Alung Technologies received USD 12 million financing from existing as well as new investors. This financing helped in commercialization of Hemolung Respiratory Assist System (RAS).
Extracorporeal CO2 Removal Devices Market Report Highlights:
- The extracorporeal CO2 machines segment dominated the market in 2024 with 52.4% of the market share and is expected to witness fastest growth due to their advanced ability to efficiently remove excess carbon dioxide from a patient's bloodstream, particularly in critical care settings.
- The COPD segment is expected to hold a considerable market share in 2024 as ECCO2R devices may permit a decrease in respiratory rate and respiratory volume, resulting in elongated expiratory time that is better adapted to high expiratory time constant of respiratory system
- The venovenous segment are expected to grow at the fastest rate during the forecast period as it offers less invasiveness by evading arterial cannulation and has the potential for early mobilization of patients
- The hospital segment accounted for the largest revenue share of 46.7% in 2024 due to their ability to manage the complexity of critical care cases requiring such advanced respiratory support.
- The extracorporeal CO? removal devices market in North America is driven by the increasing clinical adoption across specialized care settings.
- This is attributable to the growing prevalence of COPD, ARDS, and increasing adoption of advanced extracorporeal CO2 removal devices
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Access
- 1.2.4. End-use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application outlook
- 2.2.3. Access outlook
- 2.2.4. End-use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
Chapter 3. Extracorporeal CO2 Removal Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising prevalence of respiratory diseases
- 3.2.1.2. Technological advancements
- 3.2.1.3. Growing geriatric population
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High costs of devices and maintenance
- 3.3. Extracorporeal CO2 Removal Devices Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
Chapter 4. Extracorporeal CO2 Removal Devices Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Extracorporeal CO2 Removal Devices Market: Product Movement Analysis
- 4.3. Extracorporeal CO2 Removal Devices Market by Product Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Extracorporeal CO2 machines
- 4.5.1. Extracorporeal CO2 machines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Disposables
- 4.6.1. Disposables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Extracorporeal CO2 Removal Devices Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Extracorporeal CO2 Removal Devices Market: Application Movement Analysis
- 5.3. Extracorporeal CO2 Removal Devices Market by Application Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Acute Respiratory Distress Syndrome (ARDS)
- 5.5.1. Acute Respiratory Distress Syndrome (ARDS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Chronic Obstructive Pulmonary Disease (COPD)
- 5.6.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Bridge to Lung Transplant
- 5.7.1. Bridge to Lung Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Extracorporeal CO2 Removal Devices Market: Access Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Extracorporeal CO2 Removal Devices Market: Access Movement Analysis
- 6.3. Extracorporeal CO2 Removal Devices Market by Access Outlook (USD Million)
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Venovenous
- 6.5.1. Venovenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Arteriovenous
- 6.6.1. Arteriovenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Extracorporeal CO2 Removal Devices Market: End-use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Extracorporeal CO2 Removal Devices Market: End-use Movement Analysis
- 7.3. Extracorporeal CO2 Removal Devices Market by End-use Outlook (USD Million)
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.5. Hospitals
- 7.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Ambulatory Surgical Centers
- 7.6.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Clinics
- 7.7.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. Others
- 7.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Extracorporeal CO2 Removal Devices Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Regional Extracorporeal CO2 Removal Devices Market movement analysis
- 8.3. Extracorporeal CO2 Removal Devices Market: Regional Estimates & Trend Analysis by Product, Application, Access & End-use
- 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.5. North America
- 8.5.1. North America Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. U.S.
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement scenario
- 8.5.2.5. U.S. Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Canada
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement scenario
- 8.5.3.5. Canada Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. Mexico
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement scenario
- 8.5.4.5. Mexico Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Europe
- 8.5.6. Europe Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. UK
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Competitive Scenario
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement scenario
- 8.5.7.5. UK Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Germany
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Competitive Scenario
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement scenario
- 8.5.8.5. Germany Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. France
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Competitive Scenario
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement scenario
- 8.5.9.5. France Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.10. Italy
- 8.5.10.1. Key Country Dynamics
- 8.5.10.2. Competitive Scenario
- 8.5.10.3. Regulatory Framework
- 8.5.10.4. Reimbursement scenario
- 8.5.10.5. Italy Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.11. Spain
- 8.5.11.1. Key Country Dynamics
- 8.5.11.2. Competitive Scenario
- 8.5.11.3. Regulatory Framework
- 8.5.11.4. Reimbursement scenario
- 8.5.11.5. Spain Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.12. Denmark
- 8.5.12.1. Key Country Dynamics
- 8.5.12.2. Competitive Scenario
- 8.5.12.3. Regulatory Framework
- 8.5.12.4. Reimbursement scenario
- 8.5.12.5. Denmark Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.13. Sweden
- 8.5.13.1. Key Country Dynamics
- 8.5.13.2. Competitive Scenario
- 8.5.13.3. Regulatory Framework
- 8.5.13.4. Reimbursement scenario
- 8.5.13.5. Sweden Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.14. Norway
- 8.5.14.1. Key Country Dynamics
- 8.5.14.2. Competitive Scenario
- 8.5.14.3. Regulatory Framework
- 8.5.14.4. Reimbursement scenario
- 8.5.14.5. Norway Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement scenario
- 8.6.2.5. Japan Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement scenario
- 8.6.3.5. China Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement scenario
- 8.6.4.5. India Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. South Korea
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement scenario
- 8.6.5.5. South Korea Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Australia
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement scenario
- 8.6.6.5. Australia Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement scenario
- 8.6.7.5. Thailand Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement scenario
- 8.7.2.5. Brazil Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement scenario
- 8.7.3.5. Argentina Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8. Middle East & Africa
- 8.8.1. Middle East & Africa Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement scenario
- 8.8.2.5. South Africa Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement scenario
- 8.8.3.5. Saudi Arabia Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Competitive Scenario
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement scenario
- 8.8.4.5. UAE Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Competitive Scenario
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement scenario
- 8.8.5.5. Kuwait Extracorporeal CO2 Removal Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.2. Key Company Profiles
- 9.2.1. Medtronic
- 9.2.1.1. Company overview
- 9.2.1.2. Financial performance
- 9.2.1.3. Product benchmarking
- 9.2.1.4. Strategic initiatives
- 9.2.2. Getinge AB
- 9.2.2.1. Company overview
- 9.2.2.2. Financial performance
- 9.2.2.3. Product benchmarking
- 9.2.2.4. Strategic initiatives
- 9.2.3. Xenios AG
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Product benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. Medica S.P.A.
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. Aferetica srl
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. ALung Technologies, Inc.
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. ESTOR S.P.A.
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Baxter
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. X-COR Therapeutics
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives